219 related articles for article (PubMed ID: 36059685)
1. Selinexor inhibits growth of patient derived chordomas
Walker CJ; Chang H; Henegar L; Kashyap T; Shacham S; Sommer J; Wick MJ; Levy J; Landesman Y
Front Oncol; 2022; 12():808021. PubMed ID: 36059685
[TBL] [Abstract][Full Text] [Related]
2. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
3. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
[TBL] [Abstract][Full Text] [Related]
7. XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.
Crochiere ML; Hannus S; Hansen K; Becker F; Baloglu E; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2017 Dec; 8(66):110503-110516. PubMed ID: 29299164
[TBL] [Abstract][Full Text] [Related]
8. XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB.
Galinski B; Luxemburg M; Landesman Y; Pawel B; Johnson KJ; Master SR; Freeman KW; Loeb DM; Hébert JM; Weiser DA
Transl Oncol; 2021 Aug; 14(8):101114. PubMed ID: 33975179
[TBL] [Abstract][Full Text] [Related]
9. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
[TBL] [Abstract][Full Text] [Related]
10. Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.
Muz B; Azab F; de la Puente P; Landesman Y; Azab AK
Transl Oncol; 2017 Aug; 10(4):632-640. PubMed ID: 28668761
[TBL] [Abstract][Full Text] [Related]
11. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.
Richard S; Jagannath S
BioDrugs; 2022 Jan; 36(1):13-25. PubMed ID: 35113384
[TBL] [Abstract][Full Text] [Related]
12. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
[TBL] [Abstract][Full Text] [Related]
13. Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
Nooka AK; Costa LJ; Gasparetto CJ; Richardson PG; Siegel DS; Chari A; Lentzsch S; Jagannath S; Mikhael J
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e526-e531. PubMed ID: 35361554
[TBL] [Abstract][Full Text] [Related]
14. Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors.
Coutinho DF; Mundi PS; Marks LJ; Burke C; Ortiz MV; Diolaiti D; Bird L; Vallance KL; Ibáñez G; You D; Long M; Rosales N; Grunn A; Ndengu A; Siddiquee A; Gaviria ES; Rainey AR; Fazlollahi L; Hosoi H; Califano A; Kung AL; Dela Cruz FS
Med; 2022 Nov; 3(11):774-791.e7. PubMed ID: 36195086
[TBL] [Abstract][Full Text] [Related]
15. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
[TBL] [Abstract][Full Text] [Related]
16. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
17. Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma.
Mittal S; Kadamberi IP; Chang H; Wang F; Kumar S; Tsaih SW; Walker CJ; Chaluvally-Raghavan P; Charlson J; Landesman Y; Pradeep S
Exp Hematol Oncol; 2023 Sep; 12(1):78. PubMed ID: 37715291
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
19. XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.
Baek HB; Lombard AP; Libertini SJ; Fernandez-Rubio A; Vinall R; Gandour-Edwards R; Nakagawa R; Vidallo K; Nishida K; Siddiqui S; Wettersten H; Landesman Y; Weiss RH; Ghosh PM; Mudryj M
Oncotarget; 2018 Oct; 9(77):34567-34581. PubMed ID: 30349650
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]